Drug resistance interpretation: PR HIVD8 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None

PI Accessory Mutations: None

PR Other Mutations: 113V *** • 15V *** • E35D *** • M36I *** • N37D *** • K45KR *** • F57K *** • 162V *** • L63P *** • 164M *** • H69K *** • L89M *** • L8

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible Susceptible indinavir/r (IDV/r) lopinavir/r (LPV/r) Susceptible Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r)

Mutation scoring: PR

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

NRTI Mutations: M1841 ---

NNRTI Mutations: None

RT Other Mutations: K11T see . V20R see . V21I see . V20T see . V21I see . V20T see . V20T see . V20T see . V35T see . V3

Nucleoside Reverse Transcriptase Inhibitors Non-nucleoside Reverse Transcriptase Inhibitors abacavir (ABC) Low-Level Resistance doravirine (DOR) Susceptible zidovudine (AZT) Susceptible efavirenz (EFV) Susceptible etravirine (ETR) stavudine (D4T) Susceptible Susceptible didanosine (DDI) Potential Low-Level Resistance nevirapine (NVP) Susceptible emtricitabine (FTC) High-Level Resistance rilpivirine (RPV) Susceptible lamivudine (3TC) High-Level Resistance tenofovir (TDF) Susceptible

RT comments

NRTI

M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

Mutation scoring: RT HIVDB 9.5.1 (2023-11-05)

 Rule
 ABC ⇒
 AZT ⇒
 D4T ⇒
 DDI ⇒
 FTC ⇒
 3TC ⇒
 TDF ⇒

 M184I
 15
 -10
 -10
 10
 60
 60
 -10

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

INSTI Major Mutations: None INSTI Accessory Mutations: None IN Other Mutations: K14R:

s: K14R - 172V - 1112V - 1113V - 1124A - 1125A - G134N - K136KH -

Integrase Strand Transfer Inhibitors

bictegravir (BIC) Susceptible
cabotegravir (CAB) Susceptible
dolutegravir (DTG) Susceptible
elvitegravir (EVG) Susceptible
raltegravir (RAL) Susceptible

Mutation scoring: IN
HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.